NSF Linked to Gadolinium

by Administrator 9. July 2010 05:53

Over the past several years, researchers have found a correlation between the development of Nephrogenic Systemic Fibrosis and the increasing use of gadolinium-based MRI contrast agents.

 

Gadolinium, an element of the lanthanide series, is the chief component of virtually all contrast agents administered for magnetic resonance imaging. It has been linked to the development of Nephrogenic Systemic Fibrosis, formerly known as Nephrogenic Fibrosing Dermopathy. Nephrogenic Systemic Fibrosis is a systemic disorder with its most visible effects on the skin. NSF patients experience swelling and tightening of the skin.

 

The skin changes may begin as reddened or darkened patches or papules. Patients may experience burning, itching, or severe sharp pains in areas of involvement. 

 

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.

What are the FDA-approved gadolinium contrast agents?

by Administrator 8. April 2010 05:06

The FDA has approved a number of gadolinium-based contrast agents. These contrast agents include Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. 

While the use of these drugs has been associated with NSF, they still have FDA approval. One reason for maintaining this approval is that medical reports have not gathered enough information about the correlation between gadolinium and NSF. 

If you have beeen diagnosed with NSF and been exposed to a gadolinium-based contrast agent, contact the gadolimium lawyers of Williams Kherkher at 800-761-3187.

FDA Panel Recommends Restrictions on Gadolinium Use

by Administrator 30. December 2009 10:12

An FDA-appointed panel has ruled that restrictions should be placed on the use of gadolinium contrast agents (commonly used in medical imaging scans) after convincing evidence has linked the agents to a potentially fatal skin-hardening disease called nephrogenic systemic fibrosis (NSF). Sources say that NSF is a progressive disease that can cause the skin to thicken and harden in the arms, legs, and extremities.

While the FDA does not have to follow the advice of it's appointed panels, sources say that a panel recommendation often goes a long way toward implementing new regulations. 

If you or someone you love has suffered NSF or other health problems caused by gadolinium contrast agents, contact the NSF attorneys of Williams Kherkher at 800-761-3187 today.

Powered by BlogEngine.NET 1.4.5.0

BlogRoll

Download OPML file OPML

home  |  about the firm  |  attorneys  |  nsf/nsd  |  gadolinium  |  articles  |  contact us  |  blog  |  resources  |  link exchange
© Copyright 2004-2010 Williams Kherkher. Attorneys are licensed only in the state of Texas unless otherwise indicated in the biographical section. Past performance is no guarantee of future results. Williams Kherkher's primary office is located in Texas. Terms of Use. Disclaimer.
8441 Gulf Freeway, Suite 600, Houston, TX 77017-5051 -- 800-696-5341

Search Engine Optimization provided by The Search Engine Guys.